RedHill Biopharma Ltd. (RDHL)
 NASDAQ: RDHL · Real-Time Price · USD
 1.350
 -0.110 (-7.53%)
  At close: Oct 30, 2025, 4:00 PM EDT
1.350
 0.00 (0.00%)
  Pre-market: Oct 31, 2025, 5:23 AM EDT
RedHill Biopharma Revenue
RedHill Biopharma had revenue of $4.08M in the half year ending June 30, 2025, a decrease of -24.39%. This brings the company's revenue in the last twelve months to $9.55M, up 157.62% year-over-year. In the year 2024, RedHill Biopharma had annual revenue of $8.04M with 23.17% growth.
Revenue (ttm) 
 $9.55M
Revenue Growth 
 +157.62%
P/S Ratio 
 0.22
Revenue / Employee 
 $272,857
Employees 
 35
Market Cap 
4.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 8.04M | 1.51M | 23.17% | 
| Dec 31, 2023 | 6.53M | -55.27M | -89.43% | 
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% | 
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% | 
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
RDHL News
- 8 days ago - RedHill Biopharma Receives Nasdaq Staff Determination Notification - PRNewsWire
- 10 days ago - CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO - PRNewsWire
- 24 days ago - RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - PRNewsWire
- 4 weeks ago - RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - PRNewsWire
- 7 weeks ago - RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - PRNewsWire
- 2 months ago - RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win - PRNewsWire
- 2 months ago - RedHill Received Talicia® Licensing Payments Totaling $1.1 Million - PRNewsWire
- 3 months ago - RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease - PRNewsWire